

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Acetaminophen, for fever, 328
 - Adrenomedullin, in cerebral salt-wasting syndrome, 343–344
 - Adult respiratory distress syndrome, 332
 - Age considerations, 222, 227, 236–237
 - Alcohol consumption, 237–238
 - Aldosterone imbalance, in cerebral salt-wasting syndrome, 340–341
 - Anemia, 328–329
 - Aneurysmal subarachnoid hemorrhage
 - aneurysm size and location in, 223, 238
 - cerebral salt wasting in, 333, **339–352**
 - clinical features of, 381
 - cost of, 239–242
 - diagnosis of, 224–225, 305–312
 - epidemiology of, **221–233**, 247, 381
 - grading of, 225–226, 236, 238–239
 - imaging of, **305–323**
 - multilobed, 256–257
 - nontreated, 225
 - outcome of, 235–239
 - pathophysiology of, 382
 - prognosis for, 227–228
 - risk factors for, 235–239, 247
 - screening for, 241
 - treatment of
 - complications of, 237, **325–338**
 - endovascular, **271–280**
 - hydrocephalus after, 255–256, **263–271**
 - noninvasive, **305–323**
 - surgical, **247–261**
 - timing of, 226–227, 248
 - vasospasm after. See Vasospasm.
 - versus nontraumatic nonaneurysmal subarachnoid hemorrhage, 224–225
- Angiography
 - computed tomography
 - for aSAH, 224, 308–310
 - for vasospasm, 282, 292–293, 315–316
 - digital subtraction
 - for aSAH, 224, 253
 - for vasospasm, 292, 356
 - fluorescent, 253
 - magnetic resonance
 - for aSAH, 224, 310–312
 - for vasospasm, 293, 318
- Angioplasty, transluminal balloon, for vasospasm, 287–288, 357

- Angiotensin imbalance, in cerebral salt-wasting syndrome, 340–341
- Anterior parasagittal craniotomy, 250–251
- Antiinflammatory agents, for vasospasm prevention, 368–369
- Antiplatelet agents, 275–277
- Arctic Sun temperature management system, for fever, 328
- Arrhythmias, 331
- aSAH. See Aneurysmal subarachnoid hemorrhage.
- Aspirin, 275–277, 356
- Astrocytic damage, in vasospasm, 387
- Atrial natriuretic peptide, in cerebral salt-wasting syndrome, 342–343
- Axonal damage, in vasospasm, 387

B

- Bacteremia, 333
- Balloon angioplasty, transluminal, for vasospasm, 287–288, 357
- Balloon-assisted liquid polymer embolization, 272
- Basilar artery
 - aneurysm of, 223
 - vasospasm of, 298
- Bicaudate index, for hydrocephalus, 264–265
- Biomarkers
 - for aSAH, 239
 - for vasospasm, 368, **381–391**
 - astrocytic damage, 387
 - axonal damage, 387
 - calcium metabolism, 386
 - coagulation cascade, 386–387
 - endothelial activation, 385
 - endothelin, 386
 - hemoglobin degradation, 385–386
 - identification of, 383–384
 - inflammation, 384–385
 - isolation of, 383
 - neuronal damage, 387
 - nitric oxide, 386
 - proteomics of, 382
 - tissue sampling for, 382–383
- Blood, vasospasm biomarkers in, 382–383
- Blood stream infections, 333
- Blood transfusions, 328–329
- Body mass index, high, aneurysm risk in, 224
- Brain Attack Surveillance in Corpus Christi project, 227

Brain death, transcranial Doppler ultrasonography for, 299
 Brain-natriuretic peptide, in cerebral salt-wasting syndrome, 342–343
 Buspirone, for fever, 328

C

Calcium channel blockers, for vasospasm, 286–287, 355–356
 Calcium metabolism, proteins involved in, as vasospasm biomarkers, 386
 Cardiac complications, 331–332
 Cardiopulmonary bypass, deep hypothermic, 254–255
 Carotid artery, internal, vasospasm of, 297–298
 Cell-adhesion molecules, in vasospasm, 369–370
 Celsius Control System, for fever, 327–328
 Central venous pressure, in cerebral salt-wasting syndrome, 345
 Cerebral artery
 anterior, vasospasm of, 296–298
 middle
 aneurysm of, 223
 vasospasm of, 294–298
 posterior, vasospasm of, 298
 Cerebral edema, 236
 Cerebral revascularization, 256
 Cerebral salt-wasting syndrome, 333, **339–352**
 clinical relevance of, 339–340
 diagnosis of, 344–346
 historical aspects of, 339
 pathophysiology of, 340–344
 treatment of, 346–347
 vasospasm and, 354–355
 Cerebral vasospasm. *See* Vasospasm.
 Cerebrospinal fluid, vasospasm biomarkers in, 383
 Cholesterol ester hydroperoxides, as vasospasm biomarkers, 385–386
 Chromatography, for vasospasm biomarkers, 383
 Circulatory arrest, 254–255
 Claassen Physiologic Derangement Score, 325–326
 Clazosentan, for vasospasm prevention, 355
 Clipping
 history of, 271
 novel techniques for, 256–257
 temporary, 254
 versus coil embolization, 240–241
 Clonidine, for shivering, 328
 Clopidogrel, 275–277
 Coagulation cascade, 386–387
 Cocaine use, 238
 Coil embolization, 271
 techniques for, 272–274
 versus clipping, 240–241
 Color-coded duplex sonography, for vasospasm, 295–296
 Columbia University SAH Outcomes Project, 327–329, 333
 Combined Lysis of Thrombus in Brain Ischemia Using Transcranial Ultrasound and Systemic rt-PA trial, 300
 Communicating artery aneurysms, 223
 Community impact, 241
 Complement, vasospasm and, 369
 Complications, 237, **325–338**. *See also* Vasospasm.
 anemia, 328–329
 cardiac, 331–332
 electrolyte abnormalities, 332–333
 fever, 326–328
 hyperglycemia, 329–331
 infections, 333
 physiologic derangements, 325–326
 pulmonary, 332
 scope of, 325
 Computed tomography
 for aSAH, 306–308
 for hydrocephalus, 264
 for vasospasm, 281, 357
 Computed tomography angiography
 for aSAH, 224, 308–310
 for vasospasm, 282, 292–293, 315–316
 Computed tomography perfusion, for vasospasm, 282–288, 293, 316, 357
 Conivaptan, for cerebral salt-wasting syndrome, 346–347
 CONSCIOUS trials, for vasospasm prevention, 355–356, 382
 CoolGard/CoolLine system, for fever, 328
 Cooperative Aneurysm Study, 325
 Cooperative Study on Intracranial Aneurysms, 235
 Corticosteroids, for vasospasm prevention, 368
 Costs, 239–242
 Counterwarming, for fever, 328
 Craniotomy, vasospasm after, 371
 C-type natriuretic peptide, in cerebral salt-wasting syndrome, 342–343
 Cushing technique, 248
 Cyclosporine, for vasospasm prevention, 368
 Cytokines, in vasospasm, 370

D

Dandy technique, 248, 271
 Death, transcranial Doppler ultrasonography for, 299
 Deep hypothermic cardiopulmonary bypass, 254–255
 Dendroaspis natriuretic peptide, in cerebral salt-wasting syndrome, 342–343
 Depression, 239
 Dexmedetomidine, for shivering, 328
 Digital subtraction angiography
 for aSAH, 224, 253
 for vasospasm, 292, 356

Dopamine, for vasospasm, 359
 Doppler studies, transcranial. *See* Transcranial Doppler ultrasonography.
 Dott technique, 248, 254

E

Economic impact, 239–242
 Edema
 cerebral, 236
 pulmonary, 332
 Electroencephalography
 for vasospasm, 293
 intraoperative, 252–253
 Electrolyte abnormalities, 332–333
 Electrophysiologic monitoring, intraoperative, 252–253
 Embolism, pulmonary, 332
 Endothelins, elevated, in vasospasm, 370, 386
 Endovascular treatment, **271–280**
 historical perspective of, 271–272
 hydrocephalus after, 266–267
 of vasospasm, **281–290**
 techniques for, 272–278
 Enterprise stents, 274–275
 Enzyme-linked immunosorbent assay, for
 vasospasm biomarkers, 384
 Ethnic factors, 222, 227
 Extracellular fluid, vasospasm biomarkers in, 383
 Extracranial-intracranial bypass, 256

F

Family history, 222–223
 Far-lateral transcondylar extension, of lateral
 suboccipital craniectomy, 250–252
 Fentanyl, for shivering, 328
 Fever, 237, 326–328
 Fisher Scale, 226, 306–307, 354
 Flow velocity, in transcranial Doppler
 ultrasonography, 293–294
 Flow-diverting devices, 278
 Fluid therapy
 for cerebral salt-wasting syndrome, 346–347
 for vasospasm, 354–355, 357–360
 Fluorescent angiography, 253
 Frontotemporal craniotomy, 249–250

G

Gas exchange, disturbance of, 332
 Gateway balloon system, for vasospasm, 288
 Gel electrophoresis, for vasospasm biomarkers, 383
 Gender differences, 222, 227, 238
 Genotypes, in vasospasm, 371
 Glial fibrillary acid protein, in vasospasm, 387
 Global cerebral edema, 236

Glucose abnormalities, 329–331
 Glyceraldehyde-3-phosphate, as vasospasm
 biomarker, 387
 Grading, aneurysmal subarachnoid hemorrhage,
 225–226, 236, 238–239
 Guglielmi coil, 271

H

Haptoglobin, vasospasm due to, 366–367
 Headache, 221–222
 Heart disorders, 331–332
 Hemodilution, for vasospasm, 358
 Hemoglobin
 degradation products of, as biomarker, 385–386
 vasospasm due to, 366–367
 Hemorrhage, aneurysmal subarachnoid. *See*
 Aneurysmal subarachnoid hemorrhage.
 Horsely technique, 248
 Hunt and Hess Scale, 225–226, 255–256, 293
 Hydrocephalus, **263–270**
 acute, 255–256, 264
 chronic, 265
 diagnosis of, 264–265
 etiology of, 263–264
 predictive factors for, 265–266
 subacute, 264
 treatment of, 266–268
 HydroCoils, 272–274
 Hydrocortisone, for vasospasm prevention, 368
 Hyperform balloon, for vasospasm, 287–288
 Hyperglide balloon, for vasospasm, 287–288
 Hyperglycemia, 237, 329–331
 Hypermnatremia, 332–333
 Hypertension
 aneurysm risk in, 224
 as complication, 331
 Hyperthermia, in vasospasm, 367
 Hypoglycemia, 331
 Hypokalemia, 332–333
 Hypomagnesemia, 332–333
 Hyponatremia, 332–333. *See also* Cerebral
 salt-wasting syndrome.
 Hypovolemia, in cerebral salt-wasting syndrome, 345

I

Ibuprofen, for vasospasm prevention, 368–370
 Imaging, **305–323**. *See also specific modalities.*
 Immunoglobulin superfamily proteins, in vasospasm,
 369–370
 Infections, 333
 Inflammation, in vasospasm. *See* Vasospasm,
 inflammatory hypothesis of.
 Integrins, in vasospasm, 369
 Interleukins, in vasospasm, 370
 International Cooperative Study on the Timing of
 Aneurysm Surgery, 235–236, 248

International Study of Unruptured Intracranial Aneurysms, 223

International Subarachnoid Aneurysm Trial, 222, 241

Intra-aortic balloon pump, for vasospasm, 359–360

Intracellular adhesion molecules, in vasospasm, 369–370, 385

Intracranial pressure, transcranial Doppler ultrasonography for, 299–300

Intraoperative Hypothermia for Aneurysm Surgery Trial, 329–330

J

Jailing technique, 276–277

Japan Collaborative Cohort Study, 329

c-Jun N-terminal kinase, in vasospasm, 370

L

Lamina terminalis, fenestration of, 252

Lateral suboccipital craniectomy, 250–252

Leukocyte migration, in vasospasm, 369

Leukocytosis, in vasospasm, 367

Lindegaard index, in transcranial Doppler ultrasonography, 294

Lung disorders, 332

Lymphocyte function-associated-1 molecules, in vasospasm, 369

M

Mac-1, in vasospasm, 369

Magnesium

for shivering, 328

for vasospasm prevention, 356

Magnetic resonance angiography

for aSAH, 224, 310–312

for vasospasm, 293, 318

Magnetic resonance imaging

for aSAH, 310

for vasospasm, 282, 318–319

Mass spectroscopy, for vasospasm biomarkers, 383–384

Matrix coils, 272

Mean flow velocity, in transcranial Doppler ultrasonography, 293–294, 296–297

Mean transit time, in computed tomography perfusion, 282–285

Meningitis, 333, 371

Meperidine, for shivering, 328

Methylprednisolone, for vasospasm prevention, 368

Microarray analysis, for vasospasm biomarkers, 384

Microdialysis, for vasospasm monitoring, 357

Milrinone, for vasospasm, 359

Monitoring, intraoperative, 252–253

Mortality, risk factors and, 225–228, 235–239

Motor evoked potentials, intraoperative, 252

Myocardium, stunned, 331–332

N

Nafamostat mesilate, for vasospasm prevention, 369

Natriuretic peptides, in cerebral salt-wasting syndrome, 342–343

Neurofilament heavy chain SM135, in vasospasm, 387

Neuroform stents, 274

Neurogenic stunned myocardium, 331–332

Neurologic failure, 237

Neuronal damage, in vasospasm, 387

Neuron-specific enolase, in vasospasm, 387

Neuroprotection, for vasospasm prevention, 355–356

Nicardipine, for vasospasm, 286–287

Nimodipine, for vasospasm, 281, 286, 355–356

Nitinol stents, 274

Nitric oxide, depletion of, in vasospasm, 370, 386

Nonsteroidal antiinflammatory drugs, for vasospasm prevention, 368–369

Norepinephrine, for vasospasm, 359

Normovolemic therapy, for vasospasm prevention, 354–355

O

Obesity, aneurysm risk in, 224

Orbitozygomatic extension, of frontotemporal craniotomy, 249–250

Outcome, 235–239

Oxyhemoglobin, vasospasm due to, 354

P

Papaverine, for vasospasm, 286

Parasagittal craniotomy, anterior, 250–251

Phenylephrine, for vasospasm, 359

Physiologic Derangement Score, 325–326

Pneumonia, 237, 332–333

Pneumothorax, 332

Poly (ADP-ribose) polymerase, in vasospasm, 370

Positron emission tomography, for vasospasm, 316–317

Power M-mode Doppler ultrasonography, for vasospasm, 295–296

Pravastatin, for vasospasm prevention, 369

Proinflammatory agents, in vasospasm, 368

Propofol, for shivering, 328

Protein biomarkers. *See* Biomarkers.

Protein sequencing, for vasospasm biomarkers, 384

Proteomics, 382

Pterional (frontotemporal) craniotomy, 249–250

Pulmonary complications, 332

Pulsatility index, in transcranial Doppler ultrasonography, 293–294, 299–300

Q

Quality of life, 239

R

Rankin scale, modified, 226
 Rebleeding, 226, 236
 Regionalization, of cerebrovascular services, 241–242
 Renin-angiotensin-aldosterone system, dysfunction of, in cerebral salt-wasting syndrome, 340–341
 Resistance index, in transcranial Doppler ultrasonography, 293–294
 Respiratory disorders, 332
 Revascularization, cerebral, 256
 Risk factors
 for aSAH, 235–239, 247
 for vasospasm, 354
 Rocuronium, for shivering, 328
 Rupture, intraoperative, 256–257

S

Saline solutions, for cerebral salt-wasting syndrome, 346–347
 Salt wasting. *See* Cerebral salt-wasting syndrome.
 S100-B, in vasospasm, 387
 SELDI-TOF (surface-enhanced laser desorption/ionization-time-of-flight), for vasospasm biomarkers, 384
 Selectins, in vasospasm, 369
 Sentinel headaches, 222
 Sepsis, 333
 Shivering, 328
 Shunting, for hydrocephalus, 266–268
 Simvastatin, for vasospasm prevention, 355–356
 Single-photon emission computed tomography, for vasospasm, 316, 318
 Smoking, aneurysm risk in, 224
 Sodium
 abnormalities of. *See* Cerebral salt-wasting syndrome.
 replacement of, in cerebral salt-wasting syndrome, 346–347
 Somatosensory evoked potentials, intraoperative, 252
 Spencer curve, in transcranial Doppler ultrasonography, 294
 Statins, for vasospasm prevention, 238, 355–356, 369–370
 Stent grafts, 274–277
 Subarachnoid hemorrhage, aneurysmal. *See* Aneurysmal subarachnoid hemorrhage.
 Suboccipital craniectomy, lateral, 250–252
 Subtemporal extension, of frontotemporal craniotomy, 249–250
 Surface-enhanced laser desorption/ionization-time-of-flight (SELDI-TOF), for vasospasm biomarkers, 384
 Surgical treatment, **247–261**
 angiography during, 253

 anterior parasagittal approach to, 250–251
 approaches to, 248–252
 clipping techniques for
 novel, 256–257
 temporary, 254
 deep hypothermic cardiopulmonary bypass for, 254–255
 frontotemporal and extension approaches to, 249–250
 historical perspective of, 247–248
 hydrocephalus after, 255–256
 lamina terminalis fenestration in, 252
 lateral suboccipital approach to, 250–252
 monitoring during, 252–253
 revascularization in, 256
 timing of, 226–227, 248
 Sympathetic nervous system, dysfunction of, in cerebral salt-wasting syndrome, 341–342
 Symposium on the Controversies in the Management of Cerebral Aneurysms, 256
 Syndrome of inappropriate antidiuretic hormone secretion, 344–345

T

Time to peak maps, in computed tomography perfusion, 282–285
 Tobacco use, aneurysm risk in, 224
 Transcranial Doppler ultrasonography
 clinical applications of, 299–300
 data interpretation in, 296–298
 for vasospasm, 281, **291–303**, 314–315, 356–357
 indices for, 293–296
 limitations of, 298–299
 management algorithms using, 299
 technical aspects of, 293–296
 therapeutic use of, 300
 Transfusions, blood, 328–329
 Transluminal balloon angioplasty, for vasospasm, 287–288, 357
 Trauma
 transcranial Doppler ultrasonography for, 299
 vasospasm in, 371
 Triple H therapy, for vasospasm, 281, 357–360, 371
 Tumor necrosis factor α , in vasospasm, 370

U

Ultrasonography, Doppler. *See* Transcranial Doppler ultrasonography.
 Urinary tract infections, 333

V

Vascular cell adhesion molecule, in vasospasm, 370, 385
 Vasodilators, for vasospasm, 286–287

- Vasopressin, elevated, 333
 - Vasopressors, for vasospasm, 359
 - Vasospasm, 226–227, **281–290**, **353–364**
 - biomarkers for, **381–391**
 - blood transfusions in, 329
 - causes of, 292, 313, 371
 - chronic, inflammation and, 367–370
 - definitions of, 292
 - diagnosis of, 281, **291–303**, 312–319, 356–357
 - epidemiology of, 353
 - grading of, 286
 - imaging for, 281–286, 312–319
 - incidence of, 292, 313–314
 - inflammatory hypothesis of, **365–379**
 - biomarkers of, 368, 384–385
 - endothelium elevation in, 370
 - experimental evidence of, 368–369
 - free hemoglobin n, 366–367
 - haptoglobin in, 366–367
 - histopathology of, 368
 - hyperthermia in, 367
 - inflammatory response in, 367
 - leukocytosis in, 367
 - molecular evidence of, 369–370
 - nitric oxide depletion in, 370
 - location of, 292
 - monitoring of, 356–357
 - nonhemorrhagic, 371
 - prevention of, 354–356, 358–359
 - risk factors for, 354
 - transluminal balloon angioplasty for, 287–288
 - treatment of, 299, 357–360
 - vasodilators for, 286–287
 - Vecuronium, for shivering, 328
 - Ventriculitis, 333
 - Vertebral artery, vasospasm of, 298
 - Videoangiography, 253
 - Volume therapy, for vasospasm prevention, 354–355
-
- W**
- World Federation of Neurologic Surgeons grading scales, 222, 226, 238–239